RELAY THERAPEUTICS INC SIGNS SUPPLY AGREEMENT WITH PFIZER FOR ATIRMOCICLIB IN PHASE 3 CLINICAL TRIAL
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy PFE?
Source: moomoo
- Partnership Announcement: Relay Therapeutics has entered a supply agreement with Pfizer for the drug Atirmociclib.
- Clinical Trial Phase: The agreement is associated with a Phase 3 trial for Atirmociclib, indicating progress in its development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.330
Low
24.00
Averages
28.56
High
35.00
Current: 25.330
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Astellas Unveils New Oncology Data at ASCO Meeting
- Oncology Commitment: Astellas will present new data from its oncology portfolio at the 2026 ASCO Annual Meeting, reinforcing its long-term commitment to improving outcomes for cancer patients, which is expected to enhance its market position in cancer treatment.
- Bladder Cancer Research Progress: In bladder cancer, Astellas will showcase 3.5-year follow-up data from the EV-302 study evaluating the efficacy of enfortumab vedotin combined with pembrolizumab, providing crucial insights into treatment durability that may influence future clinical management decisions.
- Prostate Cancer Clinical Analysis: For prostate cancer, Astellas will share analyses from established clinical programs like EMBARK and ARCHES, offering further insights into treatment outcomes for patients with varying clinical characteristics, thereby supporting clinical decision-making and optimizing treatment strategies.
- Women's Health New Trial: Astellas will introduce the progress of the HIGHLIGHT 1 trial at ASCO, investigating the safety and efficacy of fezolinetant in women with hormone receptor-positive breast cancer receiving endocrine therapy, potentially providing new treatment options in women's health.
See More
CDC Immunization Committee Charter Rescinded
- Charter Rescission Reason: The HHS announced the rescission of the CDC's Advisory Committee on Immunization Practices charter due to an administrative error in meeting revised public notification timing requirements under the Federal Advisory Committee Act, necessitating the re-establishment of the committee and highlighting management failures.
- Committee Member Changes: In June 2025, HHS Secretary Robert F. Kennedy Jr. dismissed all 17 committee members at the time and replaced them with his chosen individuals with minimal scrutiny, raising concerns about the transparency of the committee's operations.
- Court Ruling Impact: A federal judge's stay in March 2023 on the appointment of Kennedy's 13 new ACIP members and the proposed changes to the childhood vaccination schedule illustrates the tension between political and public health policies.
- Complex Political Context: The Trump administration has appealed this ruling, reflecting the contentious nature of current vaccination policies and their potential impact on public health, while also underscoring the significant role of political factors in healthcare decision-making.
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Anti-Vaccine Bills Fail Amid Public Health Advocacy
- Anti-Vaccine Bill Failures: Dozens of anti-vaccine bills backed by the 'Make America Healthy Again' coalition have failed, indicating limited political power among supporters and showcasing the effectiveness of public health advocacy.
- Public Support for Vaccination: A February poll revealed that a bipartisan majority of Americans favor school vaccination mandates and view vaccines as safe for children, which has hindered the progress of anti-vaccine legislation in several states.
- Legislative Dynamics Shift: Despite a surge in anti-vaccine bills, particularly in states like Idaho and West Virginia, none have passed, underscoring the prioritization of public health policies over anti-vaccine initiatives.
- Future Legislative Expectations: Both public health advocates and anti-vaccine proponents anticipate ongoing debates over vaccine policies in state legislatures, suggesting that the influence of the anti-vaccine movement is rising and may lead to more proposed legislation.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
Acting FDA CDER Leader Expected to Step Down
- Leadership Change: Following Marty Makary's resignation as FDA Commissioner on May 12, acting CDER Director Tracey Beth Hoeg is also expected to step down, indicating instability at the FDA that could impact drug approval processes.
- Tenure Background: Hoeg has served as acting director since December 2025 and joined the FDA in March 2025 as a special assistant and senior advisor to Makary, highlighting her rapid ascent and influence within the agency.
- Professional Background: Trained as a sports medicine physician and epidemiologist, Hoeg criticized school closures during the COVID-19 pandemic, suggesting her public health policy stance may influence FDA decision-making.
- Market Reaction: The leadership changes at the FDA could create uncertainty in the biopharmaceutical sector, particularly regarding partnerships and R&D with countries like China, potentially affecting future deal-making and investment strategies.
See More
Astellas Unveils New Oncology Data at ASCO Meeting
- Oncology Commitment: Astellas will present new data from its oncology portfolio at the 2026 ASCO Annual Meeting, reinforcing its long-term commitment to improving outcomes for cancer patients, which is expected to enhance its market position in cancer treatment.
- Bladder Cancer Research Progress: In bladder cancer, Astellas will showcase 3.5-year follow-up data from the EV-302 study evaluating the efficacy of enfortumab vedotin combined with pembrolizumab, providing crucial insights into treatment durability that may influence future clinical management decisions.
- Prostate Cancer Clinical Analysis: For prostate cancer, Astellas will share analyses from established clinical programs like EMBARK and ARCHES, offering further insights into treatment outcomes for patients with varying clinical characteristics, thereby supporting clinical decision-making and optimizing treatment strategies.
- Women's Health New Trial: Astellas will introduce the progress of the HIGHLIGHT 1 trial at ASCO, investigating the safety and efficacy of fezolinetant in women with hormone receptor-positive breast cancer receiving endocrine therapy, potentially providing new treatment options in women's health.
See More
CDC Immunization Committee Charter Rescinded
- Charter Rescission Reason: The HHS announced the rescission of the CDC's Advisory Committee on Immunization Practices charter due to an administrative error in meeting revised public notification timing requirements under the Federal Advisory Committee Act, necessitating the re-establishment of the committee and highlighting management failures.
- Committee Member Changes: In June 2025, HHS Secretary Robert F. Kennedy Jr. dismissed all 17 committee members at the time and replaced them with his chosen individuals with minimal scrutiny, raising concerns about the transparency of the committee's operations.
- Court Ruling Impact: A federal judge's stay in March 2023 on the appointment of Kennedy's 13 new ACIP members and the proposed changes to the childhood vaccination schedule illustrates the tension between political and public health policies.
- Complex Political Context: The Trump administration has appealed this ruling, reflecting the contentious nature of current vaccination policies and their potential impact on public health, while also underscoring the significant role of political factors in healthcare decision-making.
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Anti-Vaccine Bills Fail Amid Public Health Advocacy
- Anti-Vaccine Bill Failures: Dozens of anti-vaccine bills backed by the 'Make America Healthy Again' coalition have failed, indicating limited political power among supporters and showcasing the effectiveness of public health advocacy.
- Public Support for Vaccination: A February poll revealed that a bipartisan majority of Americans favor school vaccination mandates and view vaccines as safe for children, which has hindered the progress of anti-vaccine legislation in several states.
- Legislative Dynamics Shift: Despite a surge in anti-vaccine bills, particularly in states like Idaho and West Virginia, none have passed, underscoring the prioritization of public health policies over anti-vaccine initiatives.
- Future Legislative Expectations: Both public health advocates and anti-vaccine proponents anticipate ongoing debates over vaccine policies in state legislatures, suggesting that the influence of the anti-vaccine movement is rising and may lead to more proposed legislation.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
Acting FDA CDER Leader Expected to Step Down
- Leadership Change: Following Marty Makary's resignation as FDA Commissioner on May 12, acting CDER Director Tracey Beth Hoeg is also expected to step down, indicating instability at the FDA that could impact drug approval processes.
- Tenure Background: Hoeg has served as acting director since December 2025 and joined the FDA in March 2025 as a special assistant and senior advisor to Makary, highlighting her rapid ascent and influence within the agency.
- Professional Background: Trained as a sports medicine physician and epidemiologist, Hoeg criticized school closures during the COVID-19 pandemic, suggesting her public health policy stance may influence FDA decision-making.
- Market Reaction: The leadership changes at the FDA could create uncertainty in the biopharmaceutical sector, particularly regarding partnerships and R&D with countries like China, potentially affecting future deal-making and investment strategies.
See More
